Fluid Volume Disorder Clinical Trial
Official title:
Effects of Hypertonic Saline-hydroxyethyl Starch Solution on Extracellular Water in Cardiac Surgery Patients
The aim of the study is to describe the effects of hypertonic saline/hydroxyethylstarch solution in comparison to saline solution for 25 + 25 patients undergoing coronary bypass grafting surgery (CABG) using CPB. The study fluid will be given into the venous reservoir of the CPB circuit after aortic declamping. Primary endpoints are the changes in body weight and extracellular water from baseline to the first postoperative morning.
Cardiac surgery and cardiopulmonary bypass (CPB) cause fluid retention in the body. Both
dilution of serum proteins and destruction of vascular endothelial glycocalyx cause
extravasation of the fluids. We cannot avoid this phenomenon but we can try to restore the
excess fluid into the intravascular space where it can be excreted via the kidneys.
Hypertonic saline (HS) creates an osmotic gradient across the cellular membrane, causing a
fluid shift from the intracellular space into the extracellular space and from the
extravascular space into the intravascular space. The intravascular hypertonic benefit is
short-lasting as a result of redistribution of fluid between the intravascular and
interstitial spaces. The effect can be lengthened by adding colloid component into the
solution.
The aim of the study is to describe the effects of hypertonic saline/hydroxyethylstarch
solution in comparison to saline solution for 25 + 25 patients undergoing coronary bypass
grafting surgery (CABG) using CPB. The study fluid will be given into the venous reservoir
of the CPB circuit after aortic declamping. Primary endpoints are the changes in body weight
and extracellular water from baseline to the first postoperative morning. Secondary
endpoints are the need of fluids and diuretic medication during the perioperative period.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03917446 -
Volume Responsiveness Assesment After Propofol.
|
||
Not yet recruiting |
NCT01456702 -
Risk Stratification and Goal-directed Volume Therapy
|
N/A |